[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![BPharmCatalyst Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::56121651.png) BioPharmCatalyst [@BPharmCatalyst](/creator/twitter/BPharmCatalyst) on x 29.9K followers
Created: 2025-07-24 12:32:10 UTC

$GLPG reported that its first quarter 2025 results show consistent revenues of €140.3M but a significant XX% surge in R&D expenses to €278M. Overall expenses (G&A, S&M) rose XX% to €74.5M. This led to a net loss of €259.1M, a stark contrast to Q1 2024's €99.2M profit. Operating loss widened by XXX% to €215.7M. The company is exploring divestiture of its cell therapy business but maintains strong CAR-T programs and a solid €3.1B cash balance.

See More Pre-market Movers 👇


$CYCC $PALI $ANNX $ATHE $MNOV $THAR $PSTV $ATRA $RCKT

![](https://pbs.twimg.com/media/Gwn3mqxWwAEL9P9.jpg)

XXXXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1948360559826551181/c:line.svg)

**Related Topics**
[surge](/topic/surge)
[$glpg](/topic/$glpg)

[Post Link](https://x.com/BPharmCatalyst/status/1948360559826551181)